These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11363747)

  • 1. Oral ganciclovir shows benefit for prevention of CMV disease in liver transplant recipients.
    J Int Assoc Physicians AIDS Care; 1996 Jul; 2(7):43-4. PubMed ID: 11363747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.
    Paya CV; Wilson JA; Espy MJ; Sia IG; DeBernardi MJ; Smith TF; Patel R; Jenkins G; Harmsen WS; Vanness DJ; Wiesner RH
    J Infect Dis; 2002 Apr; 185(7):854-60. PubMed ID: 11920308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
    Winston DJ; Busuttil RW
    Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group.
    Martin DF; Kuppermann BD; Wolitz RA; Palestine AG; Li H; Robinson CA
    N Engl J Med; 1999 Apr; 340(14):1063-70. PubMed ID: 10194235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir.
    Palmer SM; Grinnan DC; Diane Reams B; Steele MP; Messier RH; Duane Davis R
    Clin Transplant; 2004 Apr; 18(2):179-85. PubMed ID: 15016133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group.
    Spector SA; McKinley GF; Lalezari JP; Samo T; Andruczk R; Follansbee S; Sparti PD; Havlir DV; Simpson G; Buhles W; Wong R; Stempien M
    N Engl J Med; 1996 Jun; 334(23):1491-7. PubMed ID: 8618603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral ganciclovir in pediatric transplant recipients: a pharmacokinetic study.
    Pescovitz MD; Brook B; Jindal RM; Leapman SB; Milgrom ML; Filo RS
    Clin Transplant; 1997 Dec; 11(6):613-7. PubMed ID: 9408695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
    Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
    J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ganciclovir prophylaxis for CMV disease infrequently associated with viral resistance.
    AIDS Patient Care; 1995 Dec; 9(6):308. PubMed ID: 11361450
    [No Abstract]   [Full Text] [Related]  

  • 11. Oral ganciclovir.
    Schouten JT
    STEP Perspect; 1995; 7(3):1, 11. PubMed ID: 11362979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
    Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
    Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors.
    Winston DJ; Busuttil RW
    Transplantation; 2004 Jan; 77(2):305-8. PubMed ID: 14742998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].
    Gane E; Saliba F; Valdecasas GJ; O'Grady J; Pescovitz MD; Lyman S; Robinson CA
    Lancet; 1997 Dec; 350(9093):1729-33. PubMed ID: 9413463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
    Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B
    J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir.
    Razonable RR; van Cruijsen H; Brown RA; Wilson JA; Harmsen WS; Wiesner RH; Smith TF; Paya CV
    J Infect Dis; 2003 Jun; 187(11):1801-8. PubMed ID: 12751039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.
    Pavlopoulou ID; Syriopoulou VP; Chelioti H; Daikos GL; Stamatiades D; Kostakis A; Boletis JN
    Clin Microbiol Infect; 2005 Sep; 11(9):736-43. PubMed ID: 16104989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
    Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
    Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preemptive therapy with intravenous ganciclovir for the prevention of cytomegalovirus disease in lung transplant recipients.
    Monforte V; Román A; Gavaldà J; Bravo C; Gispert P; Pahissa A; Morell F
    Transplant Proc; 2005 Nov; 37(9):4039-42. PubMed ID: 16386621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
    Murray BM; Subramaniam S
    Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.